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Abstract Human myeloid cell nuclear differentiation antigen 
(MNDA) is a myelomonocytic lineage-specific protein that 
influences gene expression through interactions with other 
nuclear proteins and transcription factors. MNDA also self-
associates and chemical cross-linking was used to demonstrate 
that MNDA forms a dimer. C-terminal and internal deletion 
mutants were used to identify two regions in the N-terminal half 
of MNDA essential for self-association. One region contains an 
imperfect leucine zipper and the second is highly enriched in basic 
residues. The sequences that are essential for dimerization are 
separated by a highly basic amphipathic «-helical region which 
was not required for dimerization. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The human myeloid cell nuclear differentiation antigen 
(MNDA) was discovered by immunoblot-screening of nuclear 
antigens in human leukemia cell lines (K562, KG-1, U937 and 
HL 60) [1,2]. MNDA is expressed only in late-stage myeloid 
cell lines (U937, HL-60 and THP-1) that undergo monocytic 
differentiation in response to vitamin D3 induction and not in 
earlier-stage lines (K562) or lines originating from other line-
ages [2]. Leukemic cell lines expressing MNDA also differen-
tiate in response to retinoid treatment whereas MNDA null 
lines do not. An analysis of > 40 cell lines, peripheral blood, 
bone marrow and cases of leukemia by immunohistochemical 
staining as well as Northern and Western blotting confirmed 
the lineage- and stage-specific expression of MNDA [3,4]. 
MNDA is up-regulated specifically by interferon a in nearly 
all cells that exhibit constitutive expression. The MNDA pro-
moter [5] contains several consensus regulatory elements, in-
cluding c-myb [6-9], PU.l [10-18], ISRE [19] and Spl [20-23], 
consistent with MNDA's myelomonocytic lineage-specific ex-
pression and regulation by interferon a. Analysis of MNDA-
associated proteins and assessment of the effects of MNDA 
expression on promoter activities of different genes has led to 
the proposal that MNDA plays a role in transcription regu-
lation by influencing the actions of other transcription factors 
[24,25]. A related mouse protein, p202, also interacts with 
other nuclear proteins and modulates transcription [26-29]. 
To further characterize the structural features of MNDA, 
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we now identify regions of MNDA essential for self-associa-
tion. Chemical cross-linking demonstrated that MNDA forms 
a dimer. C-terminal, N-terminal and internal deletion mutants 
were used in protein-protein blotting assays (Far Western) to 
localize regions required for self-association. Regions essential 
for MNDA dimerization were mapped to an imperfect leucine 
zipper and a basic region separated by an uninvolved basic 
amphipathic oc-helical region in the N-terminal half of 
MNDA. MNDA is a member of the gene 200 cluster of in-
terferon-regulated genes [3]. Each gene contains one or two 
copies of a highly conserved 200-amino-acid region. The 200-
amino-acid conserved region is located in the C-terminal half 
of MNDA. Therefore, the regions of MNDA required for 
dimerization are not conserved in other members of the 
gene family consistent with the unique lineage-specific pattern 
of MNDA expression and diverse functional roles for mem-
bers within this gene family. 
2. Materials and methods 
2.1. Labeling of MNDA 
Recombinant MNDA was prepared using the pQE30 expression 
system as described previously [24]. To promote 125I-labeling primar-
ily in the His-tag region, the purified rMNDA was first dialyzed at 
4°C with three changes against 20 mM Tris-HCl pH 8.2, 500 mM 
NaCl, 10% glycerol, 0.1% NP-40, 1 mM PMSF to remove imidazole. 
The final 3 ml reaction mixture was 20 mM Tris-HCl pH 8.2, 500 mM 
NaCl, 10% glycerol, 0.1% NP-40, 1 mM PMSF, 500 ug rMNDA, 
5 uCi Na125i. Six lodo-Beads (Pierce Rockford, IL) were added to 
the mixture and incubated at room temperature for 3.5 min. Iodinated 
protein was separated from free 12aI with Ni2+-NTA resin. A higher 
pH (8.2 vs. 7.0) used in the iodination reaction favored incorporation 
of 12oI into the imidazole ring-containing histidine residues [30]. 
The entire MNDA-coding sequence, including the initiation codon, 
was inserted into pSG5 (Stratagene), designated pSG5-MNDA and 
was used as a template for in vitro transcription-coupled translation 
of MNDA. For each 50 ul reaction, 1 ug of supercoiled vector was 
used in the T^T T7 RNA polymerase-coupled rabbit reticulocyte 
lysate system (Promega) with incorporation of 3aS-methionine. 
2.2. Cross-linking 
In chemical cross-linking experiments, purified rMNDA was dia-
lyzed extensively against 20 mM HEPES pH 7.9, 10% glycerol, 150 
mM NaCl to remove imidazole. After dialysis, the sample was cleared 
by centrifugation and 10 ug/ml rMNDA was treated with DSG (di-
succinimidyl glutarate) (Pierce), ranging from 10 uM to 1 mM for 
various times as indicated. The samples were quenched with 50 mM 
Tris pH 8.0 and analyzed by SDS-PAGE (7.5%). Cross-linked protein 
patterns were visualized by Coomassie blue staining or immunoblot-
ting using anti-MNDA antibodies. To control for multimerization 
caused by cross-linking polyhistidine residues, the procedure was 
also performed with tag-less rMNDA produced by digesting with 
Factor Xa. In vitro translated, 35S-met-labeled MNDA was prepared 
by diluting 5 jxl of the in vitro reaction mixture to 480 jxl of 20 mM 
HEPES pH 7.9, 10% glycerol and 150 mM NaCl. Fifteen ul of DSG 
in DMSO was then added to give a final concentration range of 0.01 
to 1.00 mM. After 15 min at room temperature, reactions were termi-
nated with 50 mM Tris-HCl pH 7.5. The proteins were then TCA-
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precipitated, acetone-washed and dried by vacuum centrifugation. 
MNDA bands in SDS-PAGE were detected by autoradiography. 
2.3. Generation of MNDA deletion mutants 
The pQE30-MNDA, described previously [24], was used to prepare 
His-tagged recombinant MNDA. C-terminal deletion mutations were 
prepared from the pQE30-MNDA construct using the Erase-a Base 
System (Promega). A GST-MNDA fusion construct was prepared by 
insertion of the MNDA-coding sequence minus the AUG codon into 
pGEX-3X (Pharmacia, Piscataway, NJ) and designated pGEX-
MNDA. pGEX-MNDA was used as a template for inverse long dis-
tance PCR employing a proof-reading polymerase (Pfu, Stratagene) to 
obtain eight mutated plasmid constructs containing sequentially de-
leted blocks of sequence-encoding ~ 50 amino acids. To prepare the 
mutant PCR products, eight pairs of primers in opposite orientation, 
flanking the region to be deleted, were designed with the aid of Oligo 
software (National Biosciences) that allowed continued in-frame 
translation of the MNDA after blunt ligation. 
A construct with selective deletion of 82 N-terminal amino acids of 
the MNDA was obtained by removal of Kpnl and BstBI fragment 
from pQE30-MNDA [24], followed by gel purification, fill in and 
blunt ligation. E. coli strain of M15 was used as the host cell for 
protein expression. Another construct, with deletion of aa 84-103 
(core sequence for LDL receptor-binding motif) was prepared by 
'loop-out' mutagenesis based on a method developed by Hutchison 
et al. [31] and modified by Kunkel [32]. Briefly, the complete cDNA-
coding sequence for MNDA was excised from pQE30-MNDA and 
subcloned into M13. A 31-mer synthetic oligonucleotide containing 
sequence complementary to both 5' and 3' sequence flanking the aa 
84^103 region was annealed to single-stranded M13-MNDA template 
prepared from E. coli strain CJ216 (ung~, dut-) and extended with 
DNA polymerase. The double-stranded DNA was then ligated and 
used to transform the normal E. coli host UT481 (ung+, dut+). 
Plaques containing the oligonucleotide-directed loop-out mutation 
were selected and subsequently subcloned into pQE30 for protein 
expression. Except where indicated, all the His-tagged MNDA mu-
tants were induced and purified with the procedure described for the 
full-length MNDA [24]. Correct in-frame expression of deletion mu-
tation constructs was verified by immunoblotting and specified site of 
deletion confirmed by sequencing. 
2.4. SDS-PAGE gels, Western and Far Western blots 
All procedures and antibodies used have been described in detail 
previously [2,24]. Three rat monoclonal antibodies against MNDA 
[33] determined to bind different epitopes were mixed for Western 
blot detection of deletion mutants of MNDA. 
3. Results and discussion 
3.1. MNDA is a dimer 
The ability of MNDA to self-associate was reported earlier 
[24]. To establish the stoichiometry of self-association, chem-
ical cross-linking experiments were performed. To maintain 
the native structure of the protein complex, a short length 
of cross-bridge bifunctional linker, disuccinimidyl glutarate 
(DSG), was selected. Cross-linking experiments were per-
formed with U937 nuclear extracts, His-tagged rMNDA and 
factor Xa-treated tag-less rMNDA. Coomassie blue staining 
of SDS-PAGE analysis of purified recombinant proteins 
showed a faint band at molecular weight ~ 110 kDa (suggest-
ing dimerization of the 55 kDa monomeric MNDA). How-
ever, the results could not be confirmed using native MNDA 
in U937 nuclear protein extracts due to excessive cross-linking 
of MNDA to other nuclear proteins (data not shown). Results 
using in vitro translated 35S-met-labeled MNDA confirmed 
dimerization. With increasing cross-linker DSG concentra-
tion, a band with MT of 110 kDa equivalent to a dimer of 
MNDA was observed (Fig. 1). Agreement of results from 
both recombinant and in vitro translated MNDA indicates 
that dimerization accounts for the self-association of MNDA. 
Fig. 1. Chemical cross-linking of in vitro translated MNDA. In vi-
tro translated, 36S-met-labeled MNDA shows a cross-linked pattern 
with increasing DSG concentrations (indicated at the top of each 
lane). With increasing cross-linker DSG concentration, a specific 
band at =110 kDa (top arrow) equivalent to dimers of MNDA ap-
peared. The lower arrow identifies the monomeric form of MNDA 
(55 kDa). 
3.2. Mapping the region for MNDA self-association 
To map the region(s) involved in MNDA self-association, a 
series of terminal and internal deletion mutants of MNDA 
were tested for binding. Bacterial lysates containing roughly 
equal molar amount of MNDA and its derivatives, as assessed 
by Western blotting, were separated on SDS-PAGE and 
tested for self-association by Far Western blotting. In Fig. 
2, wild-type and mutant recombinant forms of MNDA are 
defined schematically in panel A and assessed by Western 
blot in panel B. Samples transferred to a membrane and 
probed with 125I-labeled rMNDA (Far Western) are shown 
in panel C. The results indicated that sequences within the 
C-terminal half of MNDA are not required for self-associa-
tion. On the other hand, deleting residues within the N-termi-
nal half of MNDA is deleterious to self-association. Deleting 
the specific region between aa 83 and 104 (a highly basic 
amphipathic a-helical region suspected of being a protein-
binding site in the N-terminal half of MNDA) did not inter-
fere with self-association. 
To confirm these results and attempt to localize the sites of 
interaction more precisely, eight sequential small block dele-
tion mutants of MNDA were generated (Fig. 3, panel A) and 
tested to determine ability to bind in vitro translated MNDA 
(Fig. 3, panel D). The purified internal GST-MNDA deletion 
mutants and GST alone were separated on 8% SDS-PAGE 
and detected by Coomassie blue staining (Fig. 3, panel B). 
Duplicate samples were separated by SDS-PAGE and after 
being transferred and blocked with 5% milk proteins in 
HYB-100 (20 mM HEPES pH 7.7, 100 mM KC1, 0.5 mM 
MgCl2, 0.1 mM EDTA, 0.05% NP-40, 1 mM DTT) the mem-
brane was blotted with 25 |xl of in vitro translated 35S-met-
labeled MNDA (Fig. 3, panel D) in a final 15 ml hybridiza-
tion buffer (HYB-100 and 1% milk). The autoradiogram (Fig. 
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Fig. 2. Localization of regions essential for self-association by blotting C-terminal deletion mutants with radiolabeled rMNDA. (A) Schematic 
representation of His-tagged MNDA, C-terminal deletions, N-terminal and internal MNDA deletion constructs. (B) Bacterial lysates with ex-
pressed recombinant and mutated proteins separated on a 12.5% SDS-PAGE and analyzed by Western blotting with antibodies against 
MNDA. The slowest migrating band in each lane represents the appropriate size of the recombinant mutant protein determined by sequencing. 
(C) The expressed recombinant products were tested for 125I-rMNDA binding by Far Western assay. MNDA mutants missing residues from 
the N-terminal half of MNDA bind weakly or not at all. 
3, panel D) clearly demonstrated that MNDA binds to itself 
(GST-MNDA) (Fig. 3, panel D, lane 1) but not to GST (Fig. 
3, panel D, lane 2). The highly basic MNDA region between 
aa 53 and 150 is essential for self-association since deletion of 
residues 53—100 and 101-150 inhibits self-association (Fig. 3, 
panel D, lanes 4 and 5). Results of co-precipitation with glu-
tathione-immobilized GST-MNDA beads showed that the 
same regions were required for self-association (data not 
shown). These results, along with data shown in Fig. 2, dem-
onstrated that sequence within the N-terminal half of MNDA 
is essential for self-association. 
MNDA is a 407-amino-acid nuclear protein and relevant 
structural characteristics are summarized in Fig. 4. The C-
terminal 200 aa sequence is conserved between MNDA and 
another related human gene (IF 16) as well as a cluster of 
mouse genes (202, 204, D3) located on chromosome lq 
[3,34,35]. The MNDA N-terminal region is enriched with pos-
itive charged amino acids [36]. Amino acids 87-109 form a 
basic amphipathic oe-helical region [37]. This a-helical se-
quence exhibits > 50% identity with a region in the human 
interferon regulatory factor 2 (IRF2) gene (aa 119-141), a 
known transcription repressor that binds the interferon-stimu-
lated response element (ISRE) [19]. However, the putative 
DNA-binding regions of the IRF2 and the related IRF1 
and interferon consensus sequence binding protein (ICSBP) 
are confined to the N-terminal 120 amino acids which show 
no similarity to MNDA sequence. Within the basic amphi-
pathic a-helical region (aa 84-103) and also in the C-terminal 
region (aa 388^-00) of MNDA, there are sequences matching 
the consensus LDL receptor-binding sequence of apolipopro-
tein B-100 [38]. While the N-terminal LDL receptor-binding 
motif (aa 84-103) is within the region required for dimeriza-
tion (Fig. 3), the deletion of this region (aa 83-104) had no 
effect on self-association (Fig. 2). While deleting aa 3-52 did 
not alter self-association, deleting residues 1-82 reduced bind-
ing which implicates residues 52-82 in self-association. This 
region would most likely account for inhibiting self-associa-
tion when residues 53-100 were deleted since residues 83-104 
are not important for binding. The sequence between 52 and 
82 contains an imperfect leucine zipper motif (MEKKFQG-
VACLDKLIELAKDMPSLKNLVNNL). The C-terminal de-
letion results clearly implicate residues 128-154 in self-associ-
ation and this region could account for the effect of deleting 
residues 101-150. The region between 128 and 150 is highly 
basic (GRIPVAQKRKTPNKEKTEAKRNK). Recent results 
also demonstrated that the regions essential for dimerization 
(deletions of aa 53-100 and 101-150) were also essential for 
MNDA binding to YY1 zinc finger transcription factor [25]. 
Therefore, the dimerization of MNDA could be essential for 
its ability to interact with other nuclear proteins and tran-
scription factors and the imperfect leucine zipper sequence 
in conjunction with a highly basic region flanking an N-ter-
minal basic amphipathic a-helical region (aa 83-104) defines a 
novel protein-protein interaction motif. 
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Fig. 3. Mapping MNDA dimerization region by blotting GST-MNDA internal deletion mutants with in vitro translated MNDA. (A) Schematic 
illustration of GST-MNDA and sequential internal deletion mutants. Using pGEX-MNDA as templates, PCR-based mutagenesis was per-
formed to generate eight consecutive deletion mutants of MNDA spanning the entire coding region with each lacking an = 5 0 amino acids. 
(B) Coomassie blue staining of 8% SDS-PAGE of purified GST-MNDA and its deletion mutants. Each lane was loaded with 1 (il of gluta-
thione bead associated protein (containing 50-200 ng protein). (C) Autoradiogram of SDS-PAGE separated in vitro translated MNDA. (D) 
Same samples as in panel B separated on SDS-PAGE, transferred to membrane and blotted with in vitro translated, 35S-met-labeled MNDA. 
Bands in the autoradiogram indicate positive binding to the labeled rMNDA. Lanes 4 and 5, corresponding to deletions of amino acids 53-100 
and 101-150 bind very weakly, indicating that these mutants contain sequence essential for self-association. 
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